Sugi Predict

Sugi Predict / Targets / TSSK6

TSSK6

Testis-specific serine/threonine-protein kinase 6 · Q9BXA6 · TSSK6 on Sugi Atlas →

0 patent compounds predicted against TSSK6, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to TSSK6 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Impact of tdrd9 Gene Mutations in the Therapeutic Response to L-carnitine in Oligoasthenozoospermic Men PHASE3ACTIVE_NOT_RECRUITING
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve) PHASE3WITHDRAWN
PROS-1-Male Hormonal Contraceptive Regimens on Prostate Tissue PHASE2/PHASE3COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer PHASE1/PHASE2WITHDRAWN
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer PHASE2COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety PHASE2COMPLETED
Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment PHASE2COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease nanRECRUITING
Integrated Proteomic HPLC-ESI-MS Analysis of Salivary Peptides of Preterm Newborns: a Pilot Study nanCOMPLETED
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders nanCOMPLETED
New Genes in the Carcinogenesis of Colorectal Cancer nanUNKNOWN
WEST-KOaST Study: WES Analysis of Testicular Cancer Patientsand Their First-degree Family Members nanNOT_YET_RECRUITING
Cause of Familial Testicular Cancer nanCOMPLETED
Effect of Environmental Exposures on the Egg Fertilizing Ability of Human Sperm nanCOMPLETED
Study of Sperm Molecular Factors Implicated in Male Fertility nanCOMPLETED
Azoospermia Patients nanRECRUITING
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING
Identification of Novel Targetable Kinases in SR-a GvHD nanCOMPLETED
A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib nanCOMPLETED
Cryopreservation of Prepubertal Testicular Tissue for Preservation of Fertility in Young Boys With Cancer nanRECRUITING
Warfarin Effects on Male Fertility After Cardiac Surgery nanNOT_YET_RECRUITING
Targeted Radiotherapy for Recurrent Prostate Cancer nanUNKNOWN
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study nanCOMPLETED
Dried Fruit and Postprandial Glycemia Trial nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a TSSK6 binder may also engage these)

ProteinNameSimilarity
Q925K9 — 1.000 Q925K9 →
Q9D2E1 — 0.982 Q9D2E1 →
TSSK3 Testis-specific serine/threonine-protein kinase 3 0.982 landscape →
Q965G5 — 0.964 Q965G5 →
Q5JLD8 — 0.963 Q5JLD8 →
Q9WUI1 — 0.961 Q9WUI1 →
Q2PQN9 — 0.961 Q2PQN9 →
B2MVY4 — 0.961 B2MVY4 →
Q63844 — 0.960 Q63844 →
A1IVT7 — 0.960 A1IVT7 →
Q80YP0 — 0.960 Q80YP0 →
P63318 — 0.960 P63318 →
P63319 — 0.960 P63319 →
Q6ERS4 — 0.959 Q6ERS4 →
Q9M077 — 0.959 Q9M077 →
Q4R4U2 — 0.959 Q4R4U2 →
Q9QYK9 — 0.959 Q9QYK9 →
Q8TGA9 — 0.959 Q8TGA9 →
PRKCG Protein kinase C gamma type 0.959 landscape →
O65554 — 0.959 O65554 →
Q8NJT7 — 0.958 Q8NJT7 →
Q4KM47 — 0.957 Q4KM47 →
Q2TBL8 — 0.957 Q2TBL8 →
Q03114 — 0.957 Q03114 →
A3EZ55 — 0.957 A3EZ55 →
CDK4 Cyclin-dependent kinase 4 0.957 landscape →
Q38HL5 — 0.957 Q38HL5 →
P92937 — 0.957 P92937 →
Q69Q47 — 0.957 Q69Q47 →
Q4W6D3 — 0.957 Q4W6D3 →